Hepatocellular carcinoma (HCC) is the sixth most common cause of death worldwide and the main cause of primary liver cancer. The principle problem of HCC is the poor prognosis, since advanced HCC reportedly has a median survival of only 9 months. The standard therapies are sorafenib and regorafenib, but the outcomes remain unclear. We report a 60-year-old man with advanced HCC with right adrenal gland metastasis and portal vein tumor thrombosis, who showed a complete response to multiple applications of an interdisciplinary therapy
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 pati...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Although surgery...
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and its treatment options are...
Hepatocellular carcinoma (HCC) is the third leading cause of death by cancer worldwide. The prognosi...
Hepatocellular carcinoma(HCC)is nowadays one of the leading common causes of cancer death and mostly...
Hepatocellular carcinoma is a main challenge in oncologic care. Surgery is the mainstay of treatment...
Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatoce...
Hepatocellular carcinoma (HCC) is characterized by high morbidity, high recurrence, and high mortali...
Hepatocellular carcinoma (HCC) consists of heterogeneous tumors regarding morphology, biology, and u...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies ...
Hepatocellular carcinoma (HCC) is a complex condition associated with a poor prognosis. Treatment ou...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 pati...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Although surgery...
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and its treatment options are...
Hepatocellular carcinoma (HCC) is the third leading cause of death by cancer worldwide. The prognosi...
Hepatocellular carcinoma(HCC)is nowadays one of the leading common causes of cancer death and mostly...
Hepatocellular carcinoma is a main challenge in oncologic care. Surgery is the mainstay of treatment...
Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatoce...
Hepatocellular carcinoma (HCC) is characterized by high morbidity, high recurrence, and high mortali...
Hepatocellular carcinoma (HCC) consists of heterogeneous tumors regarding morphology, biology, and u...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies ...
Hepatocellular carcinoma (HCC) is a complex condition associated with a poor prognosis. Treatment ou...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 pati...
International audienceSorafenib is a molecular-targeted therapy used in palliative treatment of adva...
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Although surgery...